162 related articles for article (PubMed ID: 38307746)
1. Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
Bennett JC; Luiten KG; O'Hanlon J; Han PD; McDonald D; Wright T; Wolf CR; Lo NK; Acker Z; Regelbrugge L; McCaffrey KM; Pfau B; Stone J; Schwabe-Fry K; Lockwood CM; Guthrie BL; Gottlieb GS; Englund JA; Uyeki TM; Carone M; Starita LM; Weil AA; Chu HY
Vaccine; 2024 Feb; 42(6):1332-1341. PubMed ID: 38307746
[TBL] [Abstract][Full Text] [Related]
2. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
3. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ
JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Masuda S; Osawa R; Hosokawa N; Nakashima K; Kamura H; Imura H; Inoue H; Matsuzaka S; Sugimoto Y; Kuwamitsu O; Motohashi I; Morikawa T; Oda R; Hoshina Y; Matono T; Teshigahara O; Sando E; Asami S; Kudo S; Akizuki N; Muto Y; Hayakawa T; Kishaba T; Ohara Y; Kubo Y; Suzuki M; Morimoto K
Expert Rev Vaccines; 2024; 23(1):213-225. PubMed ID: 38288980
[TBL] [Abstract][Full Text] [Related]
6. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years - Increasing Community Access to Testing Program, United States, July 2022-February 2023.
Fleming-Dutra KE; Ciesla AA; Roper LE; Smith ZR; Miller JD; Accorsi EK; Verani JR; Shang N; Derado G; Wiegand RE; Pilishvili T; Britton A; Link-Gelles R
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):177-182. PubMed ID: 36795625
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
[TBL] [Abstract][Full Text] [Related]
8. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
11. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
12. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
Surie D; DeCuir J; Zhu Y; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Ali H; Taghizadeh L; Gong MN; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Columbus C; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Hart KW; Swan SA; Lewis NM; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1625-1630. PubMed ID: 36580424
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022.
Petrie JG; King JP; McClure DL; Rolfes MA; Meece JK; Pattinson D; Neumann G; Kawaoka Y; Belongia EA; McLean HQ
Influenza Other Respir Viruses; 2023 Mar; 17(3):e13104. PubMed ID: 36875208
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
Cerqueira-Silva T; Shah SA; Robertson C; Sanchez M; Katikireddi SV; de Araujo Oliveira V; Paixão ES; Rudan I; Junior JB; Penna GO; Pearce N; Werneck GL; Barreto ML; Boaventura VS; Sheikh A; Barral-Netto M
PLoS Med; 2023 Jan; 20(1):e1004156. PubMed ID: 36630477
[TBL] [Abstract][Full Text] [Related]
15. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
Plumb ID; Briggs Hagen M; Wiegand R; Dumyati G; Myers C; Harland KK; Krishnadasan A; James Gist J; Abedi G; Fleming-Dutra KE; Chea N; Lee JE; Kellogg M; Edmundson A; Britton A; Wilson LE; Lovett SA; Ocampo V; Markus TM; Smithline HA; Hou PC; Lee LC; Mower W; Rwamwejo F; Steele MT; Lim SC; Schrading WA; Chinnock B; Beiser DG; Faine B; Haran JP; Nandi U; Chipman AK; LoVecchio F; Eucker S; Femling J; Fuller M; Rothman RE; Curlin ME; Talan DA; Mohr NM;
Vaccine; 2024 Apr; 42(10):2543-2552. PubMed ID: 37973512
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
18. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
[TBL] [Abstract][Full Text] [Related]
20. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes.
Buchan SA; Chung H; Brown KA; Austin PC; Fell DB; Gubbay JB; Nasreen S; Schwartz KL; Sundaram ME; Tadrous M; Wilson K; Wilson SE; Kwong JC
JAMA Netw Open; 2022 Sep; 5(9):e2232760. PubMed ID: 36136332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
